Japan's Otsuka And Oncotherapy Science Sign Peptide Vaccine Deal
This article was originally published in PharmAsia News
Executive Summary
Kawasaki-based OncoTherapy Science inked a licensing deal with Otsuka Pharmaceuticals. Under the terms of the agreement, OncoTherapy will provide Otsuka exclusive development, manufacturing and marketing rights of its peptide vaccine to treat pancreatic cancer. Oncotherapy will receive an up-front payment and royalties from Otsuka after the drug goes on sale. (Click for more-Japanese language